
Insulet Revenues Surge 34% as Omnipod 5 Dominates Global Diabetes Market
Insulet CorporationDescription
What this story covers
Insulet Corporation reported a 33.9% revenue increase to $761.7 million in Q1 2026, driven by global Omnipod 5 adoption. Despite a $30 million product correction, net income doubled, supported by strong international expansion and strategic share repurchases.
Story snapshot
CompanyInsulet Corporation
TickerPODD
VariantStandard detailed
Duration11:16
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0001145197-26-000102
Sources1
Full Story Script
Content not available for this story.